This article is more than 5 years old. Information may no longer be current.

Investigational drug for androgenetic alopecia safe, tolerable

Phase 2 trial results for SM04554, an investigational drug for androgenetic alopecia, were presented at the 74^th Annual Meeting of the American Academy of Dermatology, the drug’s manufacturer, Samumed, announced in a press release.

The multicenter, randomized, double-masked, vehicle-controlled trial included 302 patients. Patients received treatment once a day for 90 days. Posttreatment follow-up lasted 45 days.

Trial results demonstrated that SM04554 was safe, effective and well-tolerated. The treatment group showed an increase in hair count and hair density, and the vehicle group showed a decrease in both measures. At the end of the trial period, the treatment group showed a 0.15% higher increase in hair density and count compared to the vehicle group.